0000899243-23-009750.txt : 20230327 0000899243-23-009750.hdr.sgml : 20230327 20230327182243 ACCESSION NUMBER: 0000899243-23-009750 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230316 FILED AS OF DATE: 20230327 DATE AS OF CHANGE: 20230327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bellon Christine CENTRAL INDEX KEY: 0001963878 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39208 FILM NUMBER: 23765746 MAIL ADDRESS: STREET 1: BEAM THERAPEUTICS, INC. STREET 2: 238 MAIN STREET, 9TH FL. CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc. CENTRAL INDEX KEY: 0001745999 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-327-8775 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-03-16 0 0001745999 Beam Therapeutics Inc. BEAM 0001963878 Bellon Christine C/O BEAM THERAPEUTICS INC. 238 MAIN STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Legal Officer Common Stock 58441 D Stock Option (Right to Buy) 80.04 2031-03-31 Common Stock 23959 D Stock Option (Right to Buy) 69.21 2032-01-31 Common Stock 30000 D Stock Option (Right to Buy) 43.45 2033-01-31 Common Stock 35000 D Stock Option (Right to Buy) 7.22 2029-05-16 Common Stock 19946 D Stock Option (Right to Buy) 7.22 2029-05-17 Common Stock 19405 D Stock Option (Right to Buy) 110.92 2031-08-31 Common Stock 10000 D Stock Option (Right to Buy) 39.11 2032-12-30 Common Stock 25000 D Includes 9,375, 3,750, 15,000 and 12,500 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, September 30, 2021, March 31, 2022 and December 30, 2022, respectively. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The March 31, 2021, September 30, 2021 and March 31, 2022 RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The December 30, 2022 RSUs vest in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer through each vesting date. The March 31, 2021 RSUs grant was originally for 12,500 RSUs of which 3,125 RSUs have already vested. The September 30, 2021 RSUs grant was originally for 5,000 RSUs of which 1,250 RSUs have already vested. The option vests at a rate of 2.08% each month until the option is fully vested. The option grant was originally for options to purchase 25,000 shares of the Issuer's common stock of which 1,041 have already been exercised. The option vests at a rate of 2.08% each month until the option is fully vested. The option vests at a rate of 2.08% each month thereafter until the option is fully vested. The option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested. The option grant was originally for options to purchase 100,350 shares of the Issuer's common stock of which 80,404 have already been exercised. The option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested. The option grant was originally for options to purchase 42,704 shares of the Issuer's common stock of which 23,299 have already been exercised. The option vests at a rate of 2.08% each month thereafter until the option is fully vested. The option vests at a rate of 2.78% each month until the option is fully vested. Exhibit List: Exhibit 24 - Power of Attorney By: /s/ Christine Bellon 2023-03-27 EX-24 2 attachment1.htm EX-24 DOCUMENT

                           LIMITED POWER OF ATTORNEY

       The undersigned hereby constitutes and appoints John Evans, Terry-Ann
Burrell, and Jon Mahlowitz, and each of them individually, with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:

       (1)   prepare, execute in the undersigned's name and on the undersigned's
             behalf, and submit to the U.S. Securities and Exchange Commission
             (the "SEC") a Form ID, including amendments thereto, and any other
             documents necessary or appropriate to obtain codes and passwords
             enabling the undersigned to make electronic filings with the SEC
             of reports required by Section 16(a) of the Securities Exchange Act
             of 1934, as amended, or any rule or regulation of the SEC;

       (2)   execute for and on behalf of the undersigned, in the undersigned's
             capacity as officer and/or director of Beam Therapeutics Inc. (the
             "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
             accordance with Section 16(a) of the Securities Exchange Act of
             1934, as amended, and the rules thereunder;

       (3)   do and perform any and all acts for and on behalf of the
             undersigned that may be necessary or desirable to complete and
             execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete
             and execute any amendment or amendments thereto, and timely file
             such form with the SEC and any stock exchange or similar authority;
             and

       (4)   take any other action of any type whatsoever in connection with the
             foregoing that, in the opinion of each such attorney-in-fact, may
             be of benefit to, in the best interest of, or legally required by,
             the undersigned, it being understood that the documents executed
             by each such attorney-in-fact on behalf of t undersigned pursuant
             to this Power of Attorney shall be in such form and shall contain
             such tms and conditions as each such attorney-in-fact may approve
             in each such attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsecessary, or
proper to be donen the exercise of any of the rights and powers herein granted,
as fullyallntents an purposes  the undersigned might or could do if personally
present, with full poweofubitution or vocation, hereby ratiing and confirming
all that each such attorney-in-fact, or each such aney--facs substitute or
substitute shall lawfully do or cause to be done by virtue of this power of
atrneanthe rits and powers herein ted. The undersigned acknowledges that each
foregoing attorney-inact, inerng i such cacity at request of thendersigned, are
not assuming, nor is the Compa assungany  the
ndersigned respoibities to comply
wh Section 16 of the Securities Exchange o1934as ameed.

     This Pow of Attorn shall remain in fullorce and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                  [Remainder of page intentionally left blank]











       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 22nd day of March, 2023



                                          /s/ Christine Bellon
                                          ----------------------
                                          Name: Christine Bellon


















































Signature Page to Limited Power of Attorney